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INTRODUCTION
Regulation of osteoblastic differentiation is a key element in the processes of bone
development and fracture repair. One proposed regulator of osteoblastic
differentiation is transforming growth factor-beta 1 (TGF-I) as has been shown both
in cultured cells and in vivo. TGF-I has been found to affect the proliferation,
differentiation, and phenotypic expression of various connective tissue cells. (e) In
its latent form, TGF-13, exists as a high molecular weight complex. () The acidic
microenvironment created during bone resorption may regulate TGF-I, activity by
converting it from a latent to an active form.(’’) In the active form, TGF-13 is a
_25,000 dalton polypeptide. At least five closely related proteins of this family ,TGF-
r,., have so far been identified and several of them may have important roles in
regulating bone tissue activity. () TGF-8 and TGF-13 have been the most extensively
studied, and the two are interchangeable in most biological assays.(’’’) Both are
produced by various cells (including osteoblasts) and are very abundant in
bone. (’,’) Both are also known to have both inhibitory and stimulatory effects on
the proliferation of fetal rat calvarial cells(), rat osteosarcoma cells(), and mouse
calvarial-derived MC3T3.E1 cells. (’’’’’’ In vivo studies of fracture repair
demonstrated increased rates of proliferation following TGF-r, or TGF-13= treatment.
In addition, TGF-8, and TGF-13 have been shown to be regulators of extracellular
matrix proteinr’’’’) and alkaline phosphatase expression by various connective tissue
cells. (’e’’, In vivo studies have shown that both factors are capable of initiating
a repair process and callus formation in uninjured bone.() TGF-FJ and TGF-8 have
also been shown to be chemotactic agents for both fetal rat calvariae and
osteoblast-like osteosarcoma cells.() The purpose of this study is to characterize
cell motility of various osteoblast-like and fibroblast-like cells, using the wound
healing assay, to investigate the effects of TGF-I on the motility of osteoblast-like
MC3T3.E1 cells, and to explore potential cellular and molecular underlying
mechanisms.
We demonstrate that osteoblast-like cells, ROS 17/2.8 and SAOS-2, have significantly
lower motility rates than fibroblast-like EL2 and HT cells. While untreated osteoblast-
like MC3T3.E1 cells exhibit motility rates similar to the fibroblast-like cell lines,
TGF-8 decreases the motility of MC3T3.E1 cells, and its proliferative effects on the
growth of the cells is delayed. This TGF-8, mediated decrease in cell motility is not
accompanied by a change in MC3T3.E1 adhesion to fibronectin or vitronectin.
BACKGROUND
Bone Growth and Development
Although one bone appears no different from another at the histological level, bone
growth is generally classified as endochondral, intramembranous, or sutural.
Endochondral bone formation, which occurs among other places at the head of the
mandibular condyle as well as the base of the skull, takes place upon a
cartilaginous matrix model, with the cartilage immediately preceding the bone in
development. In intramembranous bone formation, which begins embryonically at
multiple sites within each bone of the cranial vault, the maxilla, and the body of the
mandible, bone develops within a soft connective tissue membrane rather that on
a cartilaginous model. Sutural bone growth occurs exclusively in the skull and
involves the deposition of bone at two locations simultaneously on either side of the
suture.
Osteoblastic Phenotype
Traditionally, differentiated cells such as osteoblasts have been identified by their
location in tissues. However, in recent decades as a result of investigations into
the relationship between genes and proteins, differentiation came to be defined as
a change in the proteins synthesized by the cell. Some of these proteins are
secreted, allowing cells to determine the shape and composition of their
environments. Conversely, the environment produces signals received by the cell,
influencing its phenotypic expression.= Differentiation, then, can be viewed as a
dynamic interaction in which neighboring cells participate collectively to determine
the structure and function of a tissue. With this idea of differentiation in mind, the
expression of the osteoblastic phenotype can be seen as a continuum along which
cells ranging from less differentiated pre-osteoblasts to more differentiated mature
osteoblasts and osteocytes may be found.()
The osteoblast is a mononucleated cell that synthesizes both collagenous and non-
collagenous bone proteins, which are deposited as osteoid, and is responsible for
the mineralization of the osteoid. The osteoblast is believed to be derived from a
multipotent mesenchymal cell or alternatively from a perivascular cell and is generally
believed to differentiate through a precursor cell or pre-osteoblast. In vivo,
osteoblasts or lining cells are found as a cellular layer covering most of the bony
surface. When the osteoblasts are actively synthesizing bone matrix, they appear
as plump cells with open-faced nuclei and abundant basophilic cytoplasm,m) When
the cells are inactive, they are more squamous in appearance, have close-faced
nuclei and are termed lining cells.
As osteoblasts secrete their matrix, some of the cells become entrapped and are
then called osteocytes. The number of osteoblasts that become osteocytes can vary
and is dependent upon the rate of bone formation. After their formation, osteocytes
lose most of their matrix forming ability and become reduced in size. These
entrapped osteocytes maintain communication with other osteocytes and with
osteoblasts through enclosed channels or canaliculi. It is this osteocyte-osteoblast
complex which must remain intact if the bone is to remain vital.
One of the hallmarks of cellular differentiation is the synthesis of phenotype-specific
macromolecules; in osteoblasts these include alkaline phosphatase, osteocalcin, and
type collagen.() Alkaline phosphatase, an enzyme essential to the process of
mineralization, has long been recognized as an osteoblastic marker. Alkaline
phosphatase is found in abundance in osteoblastic cells, as well as in cartilage cells
prior to calcification. Alkaline phosphatase is also found in other cells and is
relatively abundant in cells of the liver, kidney, intestine, and placenta.
In addition to alkaline phosphatase, several other potential markers of the
osteoblastic phenotype have been identified. For example, the presence of collagen
type I, the major constituent of the bony matrix, can be demonstrated
immunohistologically in newly synthesized osteoid.’) Type collagen has also been
shown to be synthesized in bone explants in culture, and cells isolated from calvaria
have been observed to preferentially produce type collagen. (r) Osteoblasts in
bone almost exclusively synthesize type collagen=) and probably produce very little
or no type III collagen.
Bone also contains non-collagenous proteins, the most abundant of which is Bone
Gla Protein (BGP) or osteocalcin. Osteocalcin is a small protein produced by
bone explants and osteoblast-like cell lines. Its synthesis and secretion have thus
far been exclusively described in bone forming cells and can, therefore, also be
considered a marker of the osteoblastic phenotype.
Certain hormones including parathyroid hormone (PTH), vitamin D, and
glucocorticoids have been shown to effect bone growth and mineralization. These
tissue-specific hormone-responses are also considered markers of osteoblastic cells.
The effects of PTH on osteoblastic cells has been the subject of a number of
investigations. Rao, et al. r) investigated the effects of PTH on cultures of calvarial
derived bone cells which resulted in increased levels of cAMP within the cells.
Rodan and Rodan(=) noted similar results using freshly isolated calvarial cells and
suggested that the PTH may affect the cytoskeleton, synthesis of alkaline
phosphatase and collagen, and growth of osteoblastic cells. These authors also
reviewed the evidence that osteoblasts possess receptors for 1,25(OH) vitamin D.
In addition, glucocorticoids have been shown to be involved in bone cell regulation
principally by inhibiting the growth of the cells.(=
Due to the problems and complexities inherent in trying to study osteoblastic cells
in vivo or with establishing homogenous primary osteoblastic cell cultures, numerous
c.ell lines exhibiting osteoblast-like cell characteristics have been isolated and
cultured for use in vitro. Some of these cell lines are ROS 17/2.8, derived from
a rat osteosarcoma, MC3T3.E1 ,= an immortalized clonal murine calvaria-derived cell
line, and SAOS-2,() derived from a human osteosarcoma. Majeska and Rodan(),
for example, cloned and selected ROS 17/2.8 on the basis of its osteoblastic
characteristics, namely high level of alkaline phosphatase expression,
responsiveness to PTH and 1,25(OH)= vitamin D, and formation of mineralized tissue
in vivo. Along the same line, Sudo, et al. () demonstrated the osteoblastic nature of
the MC3T3.E1 cell line on the basis of its high alkaline phosphatase activity in the
quiesient state and its ability to form hydroxyapatite mineralized matrix in culture.
0steoblast-like cell lines have also been shown to exhibit osteoblastic characteristics
in terms of collagen type production. For example, the alkaline phosphatase rich
osteoblast-like cell line ROS 17/2.8 was found to synthesize approximately 98%
collagen type whereas a more fibroblastic-like cell isolated from the same tumor,
ROS 25/1, produced 70% type collagen and 30% type III collagen.()
Using osteosarcoma cell lines,investigators have demonstrated a close correlation
between biologic responses to 1,25(OH) vitamin Da and certain osteoblastic
properties such as elevated alkaline phosphatase and the formation of bone in
subcutaneous tissues.= However, these effects at times were varied and may have
depended on the level of differentiation or maturation of the cells.
Transforming Growth Factor-
Transforming growth factors- (TGF-) are a family of polypeptides with a Mr of
_25,000 daltons. So far at least 5 forms of the growth factor, named TGF- .,
have been identified, and the biochemistry and molecular biology of the first two
factors, TGF- and TGF-=, have been studied and described in detail.( The
existence of multiple forms of TGF-8 was not well defined when much of the earlier
work with the growth factor was done. Therefore, the term TGF-8 will refer to either
TGF-13 or TGF-8 unless otherwise indicated. TGF- stimulates anchorage
independent growth and modulates the growth and differentiation of various cell
types. <’ TGF-8 has been isolated from platelets, kidney, and placenta, is very
abundant in bone, and is known to be synthesized by osteoblasts. Furthermore,
Seyedin, et al.< demonstrated that Cartilage Inducing Factor A (CIF-A), which was
isolated from bovine demineralized bone, was in fact identical in structure to TGF-
I,. Although the mechanism of action of TGF-,. on the various tissues remains
unknown, current research indicates that TGF-.= may be the prototypes of a family
of homologous polypeptides that regulate the control and development of tissues
and organisms. ()
Rosen, et al. () found that TGF-s inhibits phenotypic expression of osteoblasts and
chondroblasts and suggest that this activity may be mediated through interactions
between the extracellular matrix and the cytoskeletal elements. Wrana, et al.,
examining rat calvarial bone cell populations, found that TGF- increased the
synthesis of secreted proteins including collagen, fibronectin, and plasminogen
activator inhibitor.
The effects of TGF-,. on connective tissue cells are varied ,nd have been the
subject of a number of investigations. Noda and Rodan,() reported that TGF-
causes changes in shape, inhibits growth and suppresses alkaline phosphatase
expression in MC3T3.E1 cells. The authors further concluded that the growth factor
is abundant in bone and also promotes the differentiation of muscle derived
fibroblastic cells into cartilage. () Uneno, et al.( studied the effects of TGF- on the
MC3T3.E1 cell line and found them to be biphasic. Initially, TGF- caused an
increase in cellular differentiation to the osteoblastic phenotype with decreased
proliferation of the MC3T3.E1 cells, but chronic exposure actually stimulated cellular
proliferation and inhibited osteoblastic phenotype expression. Centrella, et al. ()
further suggest that TGF-8 probably plays a role in early bone and cartilage
development and that it tends to increase or decrease the number and activity of
certain cell populations at various stages of development.
As evidenced by these somewhat contradictory effects of TGF-s,=, it is likely that the
mechanism of action of these growth factors is complex and is dependent upon cell
type, cell surface receptors, duration of exposure to the cell, and interaction with
other intracellular and extracellular components which may function to regulate the
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effects of TGF- and TGF-8=.
Mundy and others(’a) have suggested that TGF-8 may be involved in the coupling
mechanism of bone formation and bone resorption which occurs during bone
remodeling. TGF-8 is present in bone as a latent complex, and as resorption occurs
on the surface of the bone, this osteoclastic activity is proposed to
have a role in releasing active TGF-8 from its latent form. This active TGF-8 is now
available to exert is biological effects which may include the inhibition of further
osteoclast activity and replication of osteoblast precursors, followed by differentiation
of the precursor cells, which involves secretion of matrix proteins and mineralization
of bone. (e)
Osteoblast-like Cell Motility
During embryonic development, pre-osteoblasts or. mesenchymal cells migrate at
specific times to specific locations within the developing embryo. Later as bones
are formed or as bone repair occurs, the pre-osteoblasts are triggered to
differentiate and move to where the bone is formed. This bone remodeling has also
been suggested to require local coordination of osteoblast and osteoclast position,
a concept previously described as one of the basic tenants in a hypothesis
developed by Rodan and Martin"’) to explain the increase in bone resorption caused
by dexamethasone. According to this hypothesis, dexamethasone induces bone
resorption, at least in part, by causing the osteoblasts lining the bony surface to
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move which, in turn, results in areas where the bony surface is exposed.
Osteoclasts then respond by adhering to these exposed areas, and bone resorption
occurs. Therefore, a key element in the process of bone remodeling may be the
regulation of cell movement.
Although extensive research and a great deal of literature has been devoted to
studies of embryonic cell movement, behavior, and migration, the subject of
osteoblast migration, at least in terms of quantifying the migration, has been
somewhat over-looked. However, in order to help understand the mechanisms and
factors involved in osteoblastic cell motility, information concerning the migration and
movement of other cell types should be considered to form a basis for the study of
bone cells.
Neural Crest Cells
One area that has been studied extensively is that of neural crest cell migration
during embryogenesis. In order to migrate, neural crest cells require a specific type
of substrate and a space in which to move.() As observed in scanning electron
microscopy, neural crest cells send out filopodia for use in cell translocation which
then adhere to the substrate in the extracellular matrix (ECM). The composition of
the ECM has been well-documented in the literature. Glycosaminoglycans were
among the first ECM substrates to be identified. The most abundant of the ECM
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proteins at the time of neural crest migration is hyaluronic acid, which both enlarges
the space and provides a substratum for cell progression. The subsequent
decrease in hyaluronic acid concentration has been correlated with a reduction in
cell motility and with cellular aggregation.(’) In addition to the amorphous material
in the migratory substrate, abundant fibrillar material is also found consisting mostly
of fibronectin and lesser amounts of types land III collagen. Fibronectin, a large
glycoprotein, has been proposed to play an important role in several cellular
phenomena such as migration and adhesion and has been shown to have specific
binding properties to a cell surface receptor, to collagen, and to
glycosaminoglycans.(’’) In the migration process, fibronectin fibers are believed to
play a role as anchorage sites for the filopodia sent out by neural crest cells, a view
supported by Rovasio, et al. ("’)
Fibroblast Locomotion
Fibroblasts are another cell type which has been studied in depth in terms of cell
movement and behavior. The fibroblast is a connective tissue cell of mesodermal
origin which has the capacity to both degrade and synthesize fibrillar collagen and
the other components of the interstitial connective tissue matrix. Fibroblasts move
as individual cells and do not form permanent junctions one with another.(" Here,
the author suggests that the migrational ability of the fibroblast is related to the
development of internal fibers or microfilament bundles composed of actin and
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myosin. Rapidly moving fibroblasts in the early migrational stage do not have
conspicuous stress fibers whereas slowly moving or stationary fibroblasts have well
developed stress fibers. These stress fibers are believed to be involved with
substrate adhesion, the duration of which may be directly related to the rate of cell
movement. The increased duration of the adhesions when fibroblast movement
slows down may be associated with an increased production of fibronectin by the
cell, which is known to occur, or it might be regulated intracellularly by some
environmental signal.
Cellular Adhesion
Studies have shown that certain proteins, identified as constituents of the
extracellular matrix, enhance the attachment or surface adhesion of cells. The
presence of these proteins in the ECM is significant because understanding how
cells attach to the substrate and spread may lead to an increased understanding of
cellular differentiation and migration. One of these ECM proteins, fibronectin, is a
well-characterized extracellular glycoprotein which interacts strongly with other
extracellular matrix molecules and which causes the attachment and spreading of
most cells when it is presented to them as an insoluble substrate. (’)
The evidence that fibronectin has an affinity for many types of cells is provided by
the observation that cells in solution attach preferentially to surfaces coated with the
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protein and that the adhesion of cells to collagen matrices is mediated by
fibronectin. (’) The mechanisms of cellular adhesion to fibronectin and other
extracellular matrix proteins is the subject of a number of current investigations.
Much of this research has centered around a family of cell surface receptors called
integrins.( Integrins are heterodimeric proteins which span the cell membrane,
connecting the extracellular matrix to the cytoskeleton of the cell. (’) Several
members of the integrin family have demonstrated a special affinity for extracellular
matrix proteins containing the tripeptide arginine-glycine-aspartate (RGD) sequence,
as their cell recognition site. Proteins containing the RGD sequence include
fibronectin, vitronectin, collagen, and osteopontin. (’) Decreased motility of
osteoblasts, then, could be related to an increased number of cell surface receptors
on the osteoblasts and therefore increased adhesion of the cells to the extracellular
matrix.
HYPOTHESIS AND SPECIFIC AIMS
TGF-13, has been suggested as a potential factor in coupling bone formation and
resorption during bone remodeling, which requires local changes in osteoblastic cell
position. Thus, TGF-13, may regulate osteoblast-like cell motility.
The specific aims of this thesis proposal are as follows:
Adapt an assay for cell motility of osteoblast-like (MC3T3.E1, ROS 17/2.8,
SAOS-2) and fibroblast-like (EL2 and HT) cells.
Determine the effects of TGF-13, on the growth and motility of MC3T3.E1 cells.
Perform cell adhesion assays to determine the effects of TGF-t3, on the
attachment of MC3T3.E1 cells to various natural and synthetic proteins such
as fibronectin, vitronectin, type collagen, albumin, and Peptite 2000.
Propose a mechanism for the effect of TGF-I on osteoblast-like cell motility.
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METHODS AND MATERIALS
Cell Culture and Motilitv Assay
Cells of the mouse calvarial osteoblastic cell line MC3T3.E1 < were routinely
maintained and cultured in F-12 medium containing 10% fetal calf serum (FCS) on
100 mm tissue culture plates (Falcon Laboratories). For the motility assay, cells
were plated in F-12 medium containing 2% FCS on 16 mm wells, crossmarked on
their inferior surfaces, at a density of 2 X 10" cells/cm. Six hours after plating, cells
were fed with either F-12 supplemented with 2% FCS or F-12 supplemented with 2%
FCS and 2ng/ml TGF-13, (from porcine platelets, R & D Systems, Minneapolis, MN).
After 24 hours, a linear wound was placed across the center of each well using a
rubber policeman, resulting in a cell-free area or streak of about 5 mm in width. Cell
cultures were maintained for 10-12 days and were fed every 3-4 days with either the
test or control medium. Cell movement from the position of the original streak
border, or growth front, into the clear area was determined by superimposing
photomicrographs taken at various time points using the crossmarks. The growth
front was defined at each time point as a straight line parallel to the streak with only
10 cells on the streak side over a 0.5 mm wide length of the streak border. In order
to quantitate these differences we followed the change in growth front migration over
the time of the experiment.
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To compare the motility characteristics of osteoblast-like and fibroblast-like cells, this
assay was also performed using ROS 17/2.8 and SAOS-2 osteoblast-like cells
and EL2(’), and HT(’) fibroblast-like cells.
3H Thymidine Incorporation Assay
MC3T3.E1 cells were plated on tissue culture 2-chamber slides (Nunc, Inc.,
Naperville, II) at 2 X 10’ cells/cm and wounded as described in the cell motility
assay. H-Thymidine (0.1 uCi/mL) was added at the time of wounding in both
treated and control wells. The medium containing the H-Thymidine was removed
from the wells 12-14 hours later and both treated and control cells were fixed and
autoradiographed for 7 days in N-3 emulsion (Kodak, Rochester,NY). Consequently,
the slides were developed, fixed, and stained for 6 minutes with 0.1% crystal violet.
The proportion of labeled vs. non-labeled cells at the streak border of each slide
was then determined using photomicrography. The experiment was repeated on
separate wells 3 days following placement of the wound. Quadruplicate wells were
used for each experimental time point.
Cell Growth Assay
MC3T3.E1 cells were cultured in 24 well plates (Falcon laboratories) at a density of
4 X 10’ cells/cm=. Following overnight incubation with medium containing 10%
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serum, the medium was replaced with either fresh medium or medium with 2ng/mL
TGF-13,. TGF-13 treated and control cells were counted at various time points, in
triplicate, using a Coulter Counter (Coulter Electronics Inc., Florida) following
dissociation by treatment with 0.25 % trypsin-EDTA in PBS at 37.
To evaluate the growth rates of osteoblast-like and fibroblast-like cells, this assay
was repeated using untreated ROS 17/2.8 and EL2 cells.
Cell Adhesion Assay
Non-tissue culture 100mm plates (VWR Scientific Inc., San Francisco, CA) were
coated with vitronectin, fibronectin, type collagen (Telios Pharmaceuticals, San
Diego, CA), Peptite 2000 (a synthetic oligopeptide that supports cell adhesion,
Telios) and albumin (Promega). Solutions of each protein diluted in sterile PBS
were prepared at concentrations of 0, 0.15, 0.5, 1.5, 5.0, and 25 ug/ml. Substrate
solutions (five-30ul droplets at each concentration) were plated on culture dishes and
allowed to dry at room temperature for a minimum of 24 hours. Cells preincubated
for 24 hours with 2 ng/ml TGF-8 and control cells were then placed on the coated
plates at 2 X 10 cells/cm. Following a 90 minute incubation at 37C, the medium
containing non-attached cells was removed, and the number of attached cells within
a 0.1mm= area over each droplet was counted. A minimum of eight samples for
each peptide at each concentration were evaluated in these experiments.
RESULTS
Figure 1 shows the results of a representative assay, where the initial position of the
streak border at the time of wounding in control and treated wells (Fig. la and lc,
respectively) is compared to the position of the growth front in the corresponding
plates 11 days later (Fig.lb and Fig.ld, respectively). Cells in control wells (Fig.
l b) have migrated to near confluence into the streak area. Cells on the right side
of Fig.lb have migrated from the opposite side of the streak. However, in wells
treated with TGF-I, (Fig. l d), a large portion of the cell free area remains intact 11
days after the placement of the wound, and the growth front has migrated only
about 1.0 mm from the original position of the streak border. Treatment of
MC3T3.E1 cells with TGF-13, (2ng/ml) resulted in a significant decrease in growth
front migration into the cell-free area of the wounded well (Fig. 2). Treated cells
exhibited a 3-fold reduction in motility (0.06+0.004 mm/day) compared to control
cells (0.22+0.07 mm/day).
The results of the cell growth assay indicate that TGF-13, has a delayed proliferative
effect of MC3T3.E1 cells (Fig. 3). Twenty-four hours after plating, both treated and
control cells exhibited a 70% decrease in cell number, probably due to cell death
or to cells not adhering to the culture dish. Up to day 3, cells treated with TGF-13,
showed a 3-fold decrease in growth rate compared to non-treated cells. However,
by day 7, TGF-8, treated cells demonstrated a near 2-fold increase in growth rate
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compared to control cells.
The rate of cell front migration (Fig. 4) for EL2 (rat fibroblast-like cells) was
0.29+0.03 mm/day compared to 0.07+0.01 mm/day for ROS 17/2.8 (rat osteoblast-
like cells), although growth rates of the two cell lines are similar (Fig. 5). SAOS-2
(Human osteosarcoma osteoblast-like cells) demonstrated an even slower rate of cell
motility (Fig. 6), 0.046+0.007 mm/day, compared to a rate of 0.47+__0.06 mm/day for
HT (human fibroblastic cells).
In order to better understand the role of cell proliferation in MC3T3.E1 wound
healing, we labeled dividing cells with H-thymidine. Following a 12 hour incubation
period with H-thymidine added at the time of wounding, wells treated with TGF-I,
showed an increased percentage of labeled cells at the streak border compared to
control wells (38.0+7.0 and 25.0+.05 respectively, p<0.01) (Table 1). After an
eighteen hour labeling period 3 days later, there was a similar percentage of labeled
cells at the streak border in wells treated with TGF-I (73.0+9.0) compared to
control wells (70.0+9.0, not significant). The student’s t-test was used for statistical
analysis of the results of this-assay.
In order to investigate the role of cell-matrix interactions in the observed changes in
cell motility, we carried out cell adhesion assays. (’) Peptite-2000 allowed the highest
level of attachment of cells (170 cells/0.1 mm in treated cells and 175 cells/0.1 mm=
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in control wells) with 1/2 maximal attachment at 2.5 ug/ml in each instance.
Fibronectin exhibited the next highest level of attachment (100 cells/0.1 mm= in
treated samples and 90 cells/0.1 mm= with non-treated cells) with 1/2 maximal
attachment to fibronectin occuring at protein concentrations of 4.7 ug/ml and 3.0
ug/ml for treated and non-treated cells respectively. Adhesion assays using
vitronectin as substrate failed to plateau at 25 ug/ml and therefore, 1/2 maximal
values could not be determined. Additionally, MC3T3.E1 cells did not adhere to type
collagen or albumin at any of the assayed protein concentrations since the number
of attached cells was no different than background levels (areas of the plate where
no substrate was present). However, no significant differences were found when
comparing numbers of attached cells between treated and non-treated samples for
any of the proteins used.
To evaluate possible effects of TGF-8 on the cytoskeletal structure of MC3T3.E1
cells, which could in turn effect the migratory ability of the cel!s, we stained the cells
for F-actin microfilaments, a principle component of the cytoskeleton. MC3T3.E1
cells incubated for 72 hours with TGF-8 (2ng/ml) were stained for 20 minutes with
a 5% solution of fluorescein phalloidin (Molecular Probes, Eugene, OR; 3.3
micromolar). Fluoroscopic examination of the stained cells revealed a prominent
cytoskeletal arrangement, but no differences could be found in the cystoskeletal
organization between TGF-8 treated and control MC3T3.E1 cells (Fig. 8).
DISCUSSION
We have chosen to use the MC3T3.E1 cell line to test the effects of TGF-t3, on
osteoblast-like cell motility since these cells have previously been shown to exhibit
many of the characteristics of the osteoblastic phenotype including high alkaline
phosphatase activity in the confluent state, and the ability to differentiate and
mineralize in vitro.’’ Moreover, it has previously been shown that TGF-8, at 2ng/ml
induces alkaline phosphatase activity and cell-shape changes in these cells.’
Our findings that TGF-13, stimulates the proliferation of MC3T3.E1 cells correlates with
the findings of other investigators. Vakicevic, et al. ’’ found that TGF-13, (2.5ng/mL)
inhibited MC3T3.E1 proliferation up to 24 hours but then stimulated proliferation after
48 hours. Uneno, et al. also demonstrated a similar effect on the proliferation of
MC3T3.E1 cells treated with TGF-8; a decrease in proliferation was observed up to
40 hours of treatment followed by increased cell growth after longer treatment time.
Jennings, et al. ’" reported that both TGF-13, and TGF-13, were mitogenic for chicken
embryonic calvarial bone cells. Centrella, et al. (16) have also shown that TGF-I]
stimulates replication in fetal-rat calvarial cells, but that the effect is biphasic and
depends on the concentration of TGF-13 and on cell density. Using H thymidine
incorporation, Joyce, et al. demonstrated that TGF-I (10ng/mL) triggered a 2-fold
increase in cell proliferation in fracture callus organ culture, largely comprising
connective tissue cell types. These investigators also showed that TGF-8 can
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stimulate intramembranous bone formation during fracture repair. Northern blot
analyses demonstrated peak levels of TGF-I in the hard callus 5 days after fracture
indicating that TGF-8 has a continuing role in regulating bone formation.
Alternatively, some investigators have reported that TGF-I has an inhibitory effect on
osteoblast-like cell proliferation. Noda and Rodan(’) reported the growth of
MC3T3.E1 cells was decreased by up to 40% following treatment with 2ng/mL TGF-
I. Elford, et al. () also reported a significant decrease in the growth of MC3T3.E1
cells treated with lng/mL TGF-8. Finally, Ibbotson, et al. (’) found that TGF-8 had no
effect on cell proliferation of MC3T3.E1 cells as measured by DNA content. The
authors further concluded that changes in cell proliferation do not play a role in any
of the actions of TGF-8.
The varied and at times even contradictory effects of TGF-I on proliferation of
osteoblastic cells are probably due to differences in experimental conditions, serum
type and concentration, concentration of TGF-8, and measurement techniques.
These results, then, indicate that the effects of TGF-I on the growth of osteoblast-
like cells are complex and involve numerous factors as well. () Otherwise, these
differences may be related to changes in MC3T3.E1 cells which have been
maintained for long time periods in different laboratories.
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In addition to he wound healing assay using a monolayer culture utilized in this
investigation, other techniques have been used to evaluate cell motility. Davies, et
al. (’) used charged resin beads as a substrate for migration of osteoblasts from rat
parietal bones, showing that the morphology of the cells is affected by the charge
on the beads. Pfeilschifter, et al. () used blind-well chemotaxis chambers to evaluate
the chemotactic response of osteoblast-like cells to TGF-I and TGF-t3. These
authors showed maximal chemotaxis in cells treated with 5-15 pg/ml of TGF-t3 and
TGF-8=, while 48 hour preincubation of the cells with concentrations above 100 pg/ml
of both growth factors abolished the chemotactic response. A more common
technique used in studying cell motility is a Boyden-type chamber containing gelatin-
coated polycarbonate filters. (’’) Though other techniques are available, we chose
the culture plate wound healing assay due to its simplicity of design and our initial
observation that MC3T3.E1 cells plated on tissue culture plastic differ in their
morphology when treated with TGF-I (Fig. 9), a finding previously reported by Noda
and Rodan. (")
Our findings that osteoblast-like cells exhibit reduced cell motility compared to
fibroblast-like cells is interesting in that it suggests that a decreased ability of the
cells to move may be characteristic of osteoblastic differentiation. Based on
previous studies, pre-osteoblast undifferentiated precursor cells seem to exhibit
phenotypic characteristics which are more fibroblastic than osteoblastic. The view
of the bone growth and healing process may be seen on one level as
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undifferentiated cells moving to areas where bone formation is to occur, which then
become less mobile and more differentiated until finally the cells become stationary
as mature osteoblasts. These cells then begin secreting a bony matrix, which
comprises the greater part of mature bone, and become immobilized in this matrix
as osteocytes.
The results of the adhesion assay failed to demonstrate any increase in numbers of
TGF-13, treated MC3T3.E1 cells attaching to any of the substrates tested compared
to control cells. Fibronectin, vitronectin, and type collagen were selected for use
in this assay, since they are all proteins found in the extracellular matrix. Peptite
2000 is a synthetic peptide designed for cell adhesion and one which also contains
a receptor for laminin. Albumin was used as a control since the protein is not
involved in cellular adhesion. However, it was interesting to note that both groups
of cells exhibited substrate concentration dependent attachment to fibronectin,
vitronectin, and Peptite 2000, while attachment to type collagen, the major
constituent of the extracellular matrix in bone, was not different from background
levels.
Although the cell growth assay demonstrates an increase in the rate of cell
proliferation among MC3T3.E1 cells treated with TGF-8 compared to control cells
after day three, this does not rule out the possibility of localized differences in cell
proliferation within the culture dish. The results of the H-thymidine incorporation
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assay, however, demonstrate that the differences in growth front migration between
TGF-8, treated and untreated MC3T3.E1 cells cannot be explained by different rates
of cell proliferation in this particular area. Following 72 hour incubation time with
TGF-8, cell growth is increased compared to untreated cells (Fig. 3). However, at
the same time point similar rates of proliferation are observed at the streak border
for both groups of cells. This result correlates with the findings of Zuk and
Wezeman() who found that proliferation contributed only negligibly to the migration
of osteoblast-like cells on coated culture dishes.
Potential Mechanisms of Action of TGF-8 on the Motility of Osteoblast-like Cells
The apparent effect of TGF-I in reducing the motility of MC3T3.E1 cells is a finding
which may have importance in understanding the factors which regulate bone
growth and development. Several mechanisms of the action of TGF-I can be
proposed to explain this effect on osteoblast-like cell motility. First, the growth factor
may exert its effect by causing changes in the cytoskeletal organization of the cell
which could effect its ability to spread. Based on observations that TGF-I causes
morphological changes in MC3T3.E1 cells from a cuboidal to an elongated spindle
shape,() it seemed likely that the cytoskeleton of the cell would likewise be effected.
However, our initial experiments using a phalloidin stain procedure failed to
demonstrate differences in the cytoskelton between TGF-r, treated and control
MC3T3.E1 cells. Further investigations in this area may be considered, though,
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perhaps by varying the concentration and length of treatment with TGF-13.
A second potential mechanism of action of TGF-13 in regulating osteoblast-like cell
motility is that the growth factor may trigger an increase in integrin expression or
receptors for the various ECM proteins, thus resulting in increased adherence, and
decreased motility, of the cells to substrate. While several investigators have shown
that TGF-8 regulates the expression of specific integrins for epithelial and fibroblastic
cells, =’r"’= the results of the adhesion assay do not support this mechanism of
motility regulation since pre-treatment with TGF-13 did not result in increased
attachment of MC3T3.E1 cells to the various ECM proteins used as substrate. One
possible explanation for this result may be that the cells require a longer period of
preincubation with TGF-8, in order for increased integrin expression to occur.
However, repeating our adhesion assay with cells incubated with TGF-8 for 72
hours did not produce results which differed from the findings reported here using
a 24 hour incubation period (data not shown). Also, TGF-II may not influence
integrin expression in osteoblast-like cells to the extent it does in other cell types,
as has been mentioned previously.
Third, TGF-B may regulate the production of ECM products, which in turn could
again effect adherence, thus affecting the ability of the cells to move. Previous
investigators have demonstrated that TGF-B, stimulates matrix production by bone
cells, and by differential effects on individual matrix components, including collagen
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and fibronectin, TGF-I- may also influence the nature of the matrix formed by
different bone cell populations. (e,,r) TGF-8, then may regulate osteoblast-like cell
motility by increasing production of products which form a substrate on which the
cells attach. However, this same mechanism could also arguably propose a role for
TGF-13 in increasing cell motility by stimulating the production of substrate and
giving the cells an increased area to attach and spread.
SUMMARY AND CONCLUSIONS
This investigation demonstrated a clear inhbition of MC3T3.E1 cell motility by
treatment with TGF-13,, and showed that the underlying mechanism of this inhibition
does not appear to be related to cell proliferation. Given that the exact role of TGF-
13, in reducing motility in osteoblast-like cells remains undefined, it seems likely that
several mechanisms or levels of regulation are involved, interactions with other
factors are present, and that the process is undoubtedly quite complex.
The conclusions from this investigation can be stated as follows.
Osteoblast-like ROS 17/2.8 and SAOS-2 cells have significantly lower motility
rates compared to fibroblast-like EL2 and HT cells.
TGF-13, substantially decreases cell motility in osteoblast-like MC3T3.E1 cells,
whereas its effect on the growth of the cells is delayed.
Increased cell proliferation at the streak border may contribute to the
movement of cells into the cell free area but does not explain the reduction
in MC3T3.E1 motility caused by TGF-13,.
MC3T3.E1 cells attached efficiently to fibronectin, vitronectin, and the synthetic
peptite 2000 but failed to attach to type collagen and albumin.
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Treatment with TGF-13 does not significantly effect the attachment of
MC3T3.E1 cells to the ECM proteins evaluated in this study.
Staining of f-actin filaments using fluorescein phalloidin failed to demonstrate
quantifiable quantifiable differences in cytoskeletal organization between
treated and control MC3T3.E1 cells.
31
TABLE 1
aH Thymidine incorporation in MC3T3.E1 cells
aH-Thymidine incorporation in TGF-I treated (2ng/ml) and control
MC3T3.E1 wounded cell cultures. Numbers represent % of labeled
cells _+ S.D. of eight determinations.
TIME OF H THYMIDINE
INCORPORATION INTO WELL
PERCENT OF LABELED CELLS
AT STREAK BORDER
DAY 0
WITH TGF-13 38.0+7.0"
WITHOUT TGF-I
DAY 3
25.0+5.0
WITH TGF-13 73.0+9.0"*
WITHOUT TGF-I 70.0+9.0
* p__<0.01
** N.S.
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Fiqure 1" Wound healing assay using MC3T3.E1 Cells
Arrows mark the original position of the streak border defined as a 1.0 mm section
of the streak border where approximately 10 cells are found on the cell free side of
the streak. Bar equals 1.0 mm. a- control well at time of wounding, b- control well
11 days following placement of the wound,
-
well treated with TGF-8 (2ng/ml) at
time of wounding, d- treated well 11 days following placement of wound.
CONTROL
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TGF-131
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Fiqure 2: Reduction of MC3T3.E1 cell motility by TGF-8,.
Growth front migration of MC3T3.E,1 cells treated with TGF-8 (black diamonds) and
untreated MC3T3.E1 cells (open squares) from the wound healing assay. Each
value is the mean + STD of a minimum of six determinations.
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Fiqure 3" Growth effects of TGF-B, on MC3T3.E1 cells.
Cell numbers of MC3T3.E1 cells treated with TGF-I (black diamonds) and untreated
MC3T3.E1 cells (open squares). Each value is the mean + STD of six
determinations.
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Fiqure 4: Motility of rat osteoblast-like and fibroblast-like cells.
Cell motility of ROS 17/2.8 (black diamonds) and EL2 (open squares) cells indicating
the distance (mm) that the migrating cell growth front moved from the border of the
area cleared of cells at the onset of the experiment. Each value is the mean + STD
of six determinations.
39
100
TIME (hours)
EL2
ROS 17/2.8
2OO
40
Fiaure 5: Growth of rat osteoblast-like and fibroblast-like cells.
Growth curves of ROS 17/2.8 osteoblast-like cells (black diamonds) and EL2
fibroblast-like cells (open squares) demonstrating similar initial growth characteristics.
Each value is the mean + STD of six determinations.
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Fiqure 6: Motility of human osteoblast-like and fibroblast-like cells.
Cell motility of HT human fibroblast cells (black diamonds) and SAOS-2 human
osteosarcoma cells (open squares) indicating the distance (mm) that the migtrating
cell growth front moved from the border of the area cleared of cells at the onset of
the experiment. Each value is the mean + STD of eight determinations.
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Fk]ure 7: Substrate adhesion of MC3T3.E1 cells.
Cell adhesion assays comparing numbers of TGF-8 treated (black diamonds) and
control (open squares) MC3T3.E1 cells adhering to 0.1 mm area of varying
concentrations of peptite 2000, fibronectin, vitronectin, Type collagen, and albumin.
Cells were incubated for 90 minutes. Each value is the mean + SEM of a
minimum of eight determinations.
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Figure 8: F-Actin staining of MC3T3.E1 cells using fluorescein phalloidin.
MC3T3.E1 cells treated with TGF-8 (2ng/ml) for 72 hours and control cells were
stained for 20 minutes with a 5% solution of fluorescein phalloidin. Fluoroscopic
examination failed to demonstrate quantifiable differences between control cells-a
and treated cells-b.
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Fiqure 9: Morphology of control and treated MC3T3.E1 cells.
Confluent cultures of MC3T3.E1 cells treated 8 days with and without TGF-I
(2ng/ml). Note more cuboidal, osteoblast-like appearance of control cells-a and
somewhat spindle shaped appearance of treated cells-b.
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